Zhang Da-Wei, Garuti Rita, Tang Wan-Jin, Cohen Jonathan C, Hobbs Helen H
Department of Molecular Genetics, McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, TX 75390-8591, USA.
Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13045-50. doi: 10.1073/pnas.0806312105. Epub 2008 Aug 27.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted protein that controls plasma LDL cholesterol levels by posttranslational regulation of the LDL receptor (LDLR). Previously, we showed that PCSK9 binds specifically to an EGF-like repeat (EGF-A) in LDLR and reroutes the receptor from endosomes to lysosomes rather than to the cell surface. Here, we defined the regions in LDLR and PCSK9 that are required for receptor degradation and examined the relationship between PCSK9 binding and LDLR conformation. Addition of PCSK9 to cultured hepatocytes promoted degradation of WT LDLR and of receptors lacking up to four ligand binding domains, EGF-B or the clustered O-linked sugar region. In contrast, LDLRs lacking the entire ligand binding domain or the beta-propeller domain failed to be degraded, although they bound and internalized PCSK9. Using gel filtration chromatography, we assessed the effects of PCSK9 binding on an acid-dependent conformational change that happens in the extracellular domain of the LDLR. Although PCSK9 prevented the reduction in hydrodynamic radius of the receptor that occurs at a reduced pH, the effect was not sufficient for LDLR degradation. A truncated version of PCSK9 containing the prodomain and the catalytic domain, but not the C-terminal domain, bound the receptor but did not stimulate LDLR degradation. Thus, domains in both the LDLR and PCSK9 that are not required for binding (or internalization) are essential for PCSK9-mediated degradation of the LDLR.
前蛋白转化酶枯草杆菌蛋白酶/kexin 9型(PCSK9)是一种分泌蛋白,通过对低密度脂蛋白受体(LDLR)的翻译后调控来控制血浆低密度脂蛋白胆固醇水平。此前,我们发现PCSK9特异性结合LDLR中的一个表皮生长因子样重复序列(EGF-A),并将该受体从内体重新导向溶酶体,而非细胞表面。在此,我们确定了LDLR和PCSK9中受体降解所需的区域,并研究了PCSK9结合与LDLR构象之间的关系。将PCSK9添加到培养的肝细胞中可促进野生型LDLR以及缺失多达四个配体结合结构域、EGF-B或成簇O-连接糖区域的受体的降解。相比之下,缺失整个配体结合结构域或β-螺旋桨结构域的LDLR虽能结合并内化PCSK9,但未能被降解。我们使用凝胶过滤色谱法评估了PCSK9结合对LDLR细胞外结构域发生的酸依赖性构象变化的影响。尽管PCSK9阻止了受体在酸性降低时流体动力学半径的减小,但这种作用不足以导致LDLR降解。一个包含前结构域和催化结构域但不包含C末端结构域的PCSK9截短版本能结合受体,但不会刺激LDLR降解。因此,LDLR和PCSK9中对于结合(或内化)并非必需的结构域对于PCSK9介导的LDLR降解至关重要。